ClinicalTrials.gg
CompletedNCT00426660Updated Jun 29, 2016Results posted

Expanded Access Program for Maraviroc At Multiple Centers

A Phase 3 interventional study of maraviroc in HIV Infections, sponsored by ViiV Healthcare. Completed at 361 sites in 26 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-06-29.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,047
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
Largest of 44
1,047 · median 36
Started
2007
with 4 others
Phase 3
7 of 44
none open now
Registered
2nd of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one has the largest enrollment, is one of 5 that started in 2007, is one of 7 in phase 3, and was the 2nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV Infections
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be failing to achieve adequate virologic suppression on their current regimen and have -1 RNA greater than or equal to 1000 copies/ml, at screening
  • Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay
  • Minimum age must be 16 years or minimum adult age as determined by local regulatory authorities or directed by local law.

Exclusion criteria

Exclusion Criteria:

  • Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trial or having previously prematurely discontinued Maraviroc in trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Enrollment
1,047 participants (actual)

Study arms

  • Experimental
    1

    Drug: maraviroc

Interventions

  • The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)

    AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.

    Time frame: Baseline up to Week 144

  2. Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities

    Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3, Severe =events that interrupted participants usual daily activity and traditionally required systemic drug therapy or other treatment.

    Time frame: Baseline up to Week 144

  3. Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities

    Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 4, Very Severe = events which were unacceptable and intolerable or were irreversible or caused the participant to be in imminent danger of death.

    Time frame: Baseline up to Week 144

  4. Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses

    Treatment-emergent AIDS-defining opportunistic illnesses based on investigator classification guided by a predefined list of clinical Category C adverse events per Center for Disease Control (CDC) HIV Classification System. Includes events occurring up to 30 days after last dose of study drug.

    Time frame: Baseline up to Week 144

  5. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load

    Time frame: Baseline up to Week 144

  6. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell Counts

    Time frame: Baseline up to Week 144

  7. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on Therapy

    Time frame: Baseline up to Week 144

  8. Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by Gender

    Treatment-emergent AEs by gender that occurred up to 30 days after the last dose of study medication.

    Time frame: Baseline up to Week 144

  9. Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Race

    Treatment-emergent AEs by race that occurred up to 30 days after the last dose of study medication.

    Time frame: Baseline up to Week 144

  10. Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Age

    Treatment-emergent AEs by age that occurred up to 30 days after the last dose of study medication.

    Time frame: Baseline up to Week 144

  11. Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status

    Treatment emergent AEs by hepatis B and hepatitis C serology status that occurred up to 30 days post last dose.

    Time frame: Baseline up to Week 144

Secondary outcomes

  1. Percentage of Participants With ≥0.5 log10 Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)

    Defined as HIV-1 RNA levels \< 400 Copies/mL or at least 0.5 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.

    Time frame: Baseline up to Week 144

  2. Percentage of Participants With ≥1.0 log10 Reduction From Baseline in HIV 1 RNA

    Defined as HIV-1 RNA levels \< 400 copies/mL or at least 1.0 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.

    Time frame: Baseline up to Week 144

  3. Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL

    Limit of quantification defined as \<400 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.

    Time frame: Baseline up to Week 144

  4. Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL

    Limit of quantification defined as \<50 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.

    Time frame: Baseline up to Week 144

  5. Change From Baseline in CD4 Cell Count

    Change from baseline in cluster of differentiation 4 helper T cells (CD4) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.

    Time frame: Baseline up to Week 144

  6. Change From Baseline in CD4 Cell Count Percent

    Change from baseline in CD4 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.

    Time frame: Baseline up to Week 144

  7. Change From Baseline in CD8 Cell Count

    Change from baseline in cluster of differentiation 8 suppressor T cells (CD8) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.

    Time frame: Baseline up to Week 144

  8. Change From Baseline in CD8 Cell Count Percent

    Change from baseline in CD8 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.

    Time frame: Baseline up to Week 144

  9. Median Time to Virologic Failure

    Computed as time from the first dose of study medication to the loss of virologic response. Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥ 0.5 log10 copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.

    Time frame: Day 1 up to Week 144

  10. Percentage of Participants With Changes in HIV-1 RNA Level in Participants Meeting the Definition of Virologic Failure

    Reasons for virologic failure: A) failure to achieve a reduction in HIV-1 RNA\>=0.5 log10 copies/ml from baseline (BL) by second viral load determination (unless below level of quantification \[LOQ\]); B) \>=0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from BL \>0.5 log10 copies/ml ; C) HIV-1 RNA \>1000 copies/ml after having achieved an HIV-1 RNA below LOQ.

    Time frame: Baseline up to Week 144

  11. Percentage of Participants With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure

    Tropism status (CCR5 \[R5\], CXCR4 \[X4\], Dual Mixed \[DM\], or Non-reportable \[NR\]) at Screening (Scr) and time of virologic failure (V fail). Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥0.5 log10 copies/mL by second viral load determination (unless viral load was below lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.

    Time frame: Screening up to Week 144

  12. Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau

    Resistance to maravroc in viruses from participants failing therapy with R5 virus was investigated using the in vitro phenotypic (drug susceptibility) assay. The number of participants who failed with R5 virus were assessed successfully for maraviroc susceptibility at Baseline and Last on--treatment (Week 144). Samples were analyzed for change from Baseline to time of virologic failure in IC 50 and presence of plateau. A maximal percent inhibition (MPI) \<95% established as a plateau in inhibition at high concentrations of maraviroc was used to identify viruses which had reduced phenotypic susceptibility to maraviroc.

    Time frame: Baseline up to Week 144

  13. Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)

    Virus from participants who experienced virologic failure was analyzed for resistance to maraviroc. Resistance testing was performed on archived samples of participants which were available pre--treatment at time of virologic failure. For participants who met definition of virologic failure during the trial, the sequencing of the V3 loop of HIV--1 viral envelope gp 120 was evaluated to identify any amino acid changes concomitant with decreased susceptibility to maraviroc.

    Time frame: Baseline up to Week 144

07

Results

Posted Oct 17, 2011
Limitations and caveats
Viral loads were not available for subjects uniformly as this expanded access study followed local country guidelines and practices that could vary significantly between countries, and testing frequency may have been affected by insurance status.

Participant flow

Participant flow — Overall Study
MilestoneMaraviroc
Started1047
Treated1032
Safety analysis set1032
Completed916
Not completed131
Withdrew: Death14
Withdrew: Adverse event23
Withdrew: Insufficient clinical response22
Withdrew: Lost to follow-up15
Withdrew: Other23
Withdrew: Withdrawal by subject18
Withdrew: Protocol violation1
Withdrew: Enrolled not treated15

Outcome measures

PrimaryPercentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)

AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)
percentage of participantsMaraviroc
Grade 3 AE: all causality13.2
Grade 3 AE: treatment related2.4
Grade 4 AE: all causality6.3
Grade 4 AE: treatment related1.6
PrimaryPercentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities

Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3, Severe =events that interrupted participants usual daily activity and traditionally required systemic drug therapy or other treatment.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities
percentage of participantsMaraviroc
Alanine aminotransferase (ALT) (n=1013)2.17
Aspartate aminotransferase (AST) (n=1013)2.07
Absolute Neutrophil Count (n=1004)0.70
Alkaline Phosphatase (n=1014)0.39
Creatinine (n=1014)0.49
Gamma-glutamyl transpeptidase (GGT) (n=1014)4.73
Hemoglobin (n=1005)0.20
Hyperbilirubinemia (n=1013)1.28
Hyperuricemia (n=1014)0.69
Hypophosphatemia (n=1014)0.20
Lipase (n=409)4.40
Platelets (n=997)1.50
Potassium (hyperkalemia) (n=1014)0.10
Serum Amylase (n=1014)4.83
Sodium (hypernatremia) (n=1014)0.10
Triglycerides (n=1014)4.73
PrimaryPercentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities

Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 4, Very Severe = events which were unacceptable and intolerable or were irreversible or caused the participant to be in imminent danger of death.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities
percentage of participantsMaraviroc
ALT (n=1013)0.79
AST (n=1013)0.39
Absolute Neutrophil Count (n=1004)0.20
Alkaline Phosphatase (n=1014)0.00
Creatinine (n=1014)0.10
GGT (n=1014)1.48
Hemoglobin (n=1005)0.10
Hyperbilirubinemia (n=1013)0.30
Hyperuricemia (n=1014)0.10
Hypophosphatemia (n=1014)0.00
Lipase (n=409)1.22
Platelets (n=997)0.30
Potassium (hyperkalemia) (n=1014)0.20
Serum Amylase (n=1014)0.30
Sodium (hypernatremia) (n=1014)0.20
Triglycerides (n=1014)1.97
PrimaryPercentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses

Treatment-emergent AIDS-defining opportunistic illnesses based on investigator classification guided by a predefined list of clinical Category C adverse events per Center for Disease Control (CDC) HIV Classification System. Includes events occurring up to 30 days after last dose of study drug.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses
percentage of participantsMaraviroc
AIDS encephalopathy0.1
Bone tuberculosis0.1
Cytomegalovirus infection0.2
Extrapulmonary tuberculosis0.1
Meningitis cryptococcal0.1
Meningitis tuberculous0.1
Mycobacterium avium complex infection0.1
Mycobacterium kansasii infection0.1
Oesophageal candidiasis0.6
Pancreatitis bacterial0.1
Pneumocystis jiroveci pneumonia0.1
Progressive multifocal leukoencephalopathy0.1
Pulmonary tuberculosis0.5
Toxoplasmosis0.1
B-cell lymphoma0.1
Hodgkin's disease0.1
Kaposi's sarcoma0.2
Encephalopathy0.1
PrimaryPercentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load
Time frame:
Baseline up to Week 144

No measurements were reported for this outcome.

PrimaryPercentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell Counts
Time frame:
Baseline up to Week 144

No measurements were reported for this outcome.

PrimaryPercentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on Therapy
Time frame:
Baseline up to Week 144

No measurements were reported for this outcome.

PrimaryPercentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by Gender

Treatment-emergent AEs by gender that occurred up to 30 days after the last dose of study medication.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by Gender
percentage of participantsMaraviroc
Male (n=827)69.6
Female (n=205)73.7
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (AEs) by Race

Treatment-emergent AEs by race that occurred up to 30 days after the last dose of study medication.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Race
percentage of participantsMaraviroc
White (n=817)68.5
Black (n=106)67.9
Asian (n=54)88.9
Other Unspecified (n=55)85.5
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (AEs) by Age

Treatment-emergent AEs by age that occurred up to 30 days after the last dose of study medication.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Age
percentage of participantsMaraviroc
<18 years (n=1)100.0
18 to 44 years (n=515)71.7
45 to 64 years (n=493)68.6
>=65 years (n=23)82.6
PrimaryPercentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status

Treatment emergent AEs by hepatis B and hepatitis C serology status that occurred up to 30 days post last dose.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status
percentage of participantsMaraviroc
HBV: negative (n=897)71.3
HBV: positive (n=60)65.0
HBV: missing: (n=75)64.0
HCV: negative (n=794)72.7
HCV: positive (n=158)62.7
HCV: missing (n=80)63.8
SecondaryPercentage of Participants With ≥0.5 log10 Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)

Defined as HIV-1 RNA levels \< 400 Copies/mL or at least 0.5 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With ≥0.5 log10 Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)
percentage of participantsMaraviroc
Day 2-7 (n=26)46.2
Week 2 (n=226)93.8
Week 4 (n=773)93
Week 8 (n=761)93.2
Week 12 (n=756)94
Week 16 (n=155)87.7
Week 20 (n=131)93.1
Week 24 (n=557)91.9
Week 32 (n=202)93.1
Week 40 (n=227)91.2
Week 48 (n=228)89
Week 60 (n=160)90
Week 72 (n=125)88
Week 84 (n=79)84.8
Week 96 (n=48)91.7
Week 108 (n=18)100
Week 120 (n=9)100
Week 132 (n=4)100
Week 144 (n=1)100
SecondaryPercentage of Participants With ≥1.0 log10 Reduction From Baseline in HIV 1 RNA

Defined as HIV-1 RNA levels \< 400 copies/mL or at least 1.0 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With ≥1.0 log10 Reduction From Baseline in HIV 1 RNA
percentage of participantsMaraviroc
Day 2-7 (n=26)30.8
Week 2 (n=226)90.3
Week 4 (n=773)90.2
Week 8 (n=761)91.2
Week 12 (n=756)91.3
Week 16 (n=155)82.6
Week 20 (n=131)89.3
Week 24 (n=557)89
Week 32 (n=202)90.1
Week 40 (n=227)87.7
Week 48 (n=228)86.4
Week 60 (n=160)85.6
Week 72 (n=125)83.2
Week 84 (n=79)79.7
Week 96 (n=48)85.4
Week 108 (n=18)100
Week 120 (n=9)100
Week 132 (n=4)100
Week 144 (n=1)100
SecondaryPercentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL

Limit of quantification defined as \<400 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL
percentage of participantsMaraviroc
Baseline (n=979)6.7
Day 2-7 (n=26)3.8
Week 2 (n=226)58.8
Week 4 (n=773)72.7
Week 8 (n=761)78.8
Week 12 (n=756)82.5
Week 16 (n=155)75.5
Week 20 (n=131)83.2
Week 24 (n=557)84.4
Week 32 (n=202)83.7
Week 40 (n=227)81.1
Week 48 (n=228)80.7
Week 60 (n=160)78.1
Week 72 (n=125)72.8
Week 84 (n=79)74.7
Week 96 (n=48)75.0
Week 108 (n=18)88.9
Week 120 (n=9)77.8
Week 132 (n=4)100
Week 144 (n=1)100
SecondaryPercentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL

Limit of quantification defined as \<50 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL
percentage of participantsMaraviroc
Baseline (n=979)1.7
Day 2-7 (n=26)0.0
Week 2 (n=226)19.9
Week 4 (n=773)30.1
Week 8 (n=761)43.1
Week 12 (n=756)45.8
Week 16 (n=155)37.4
Week 20 (n=131)42.7
Week 24 (n=557)55.8
Week 32 (n=202)57.4
Week 40 (n=227)54.6
Week 48 (n=228)54.8
Week 60 (n=160)51.9
Week 72 (n=125)49.6
Week 84 (n=79)55.7
Week 96 (n=48)54.2
Week 108 (n=18)77.8
Week 120 (n=9)44.4
Week 132 (n=4)75.0
Week 144 (n=1)100
SecondaryChange From Baseline in CD4 Cell Count

Change from baseline in cluster of differentiation 4 helper T cells (CD4) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.

Time frame:
Baseline up to Week 144
Reported as:
Mean · cells/uL
Change From Baseline in CD4 Cell Count
cells/uLMaraviroc
Day 2-7 (n=6)28.5 ± 76.18
Week 2 (n=213)49.7 ± 93.15
Week 4 (n=762)68.9 ± 124.31
Week 8 (n=739)94.5 ± 122.94
Week 12 (n=738)95.7 ± 124.42
Week 16 (n=149)85.9 ± 124.37
Week 20 (n=130)106.6 ± 112.26
Week 24 (n=552)127.8 ± 139.42
Week 32 (n=197)124.1 ± 150.44
Week 40 (n=232)129.2 ± 144.31
Week 48 (n=222)140.5 ± 154.46
Week 60 (n=161)134.0 ± 151.52
Week 72 (n=124)147.0 ± 160.92
Week 84 (n=72)141.1 ± 147.55
Week 96 (n=50)160.3 ± 160.78
Week 108 (n=19)242.9 ± 167.06
Week 120 (n=8)117.9 ± 203.49
Week 132 (n=4)179.0 ± 109.94
Week 144 (n=1)93.0 ± NA
SecondaryChange From Baseline in CD4 Cell Count Percent

Change from baseline in CD4 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.

Time frame:
Baseline up to Week 144
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD4 Cell Count Percent
percentage of lymphocytesMaraviroc
Days 2-7 (n=6)-1.3 ± 1.56
Week 2 (n=206)1.8 ± 3.79
Week 4 (n=733)1.6 ± 4.84
Week 8 (n=722)1.4 ± 6.12
Week 12 (n=708)1.6 ± 5.45
Week 16 (n=141)1.9 ± 4.63
Week 20 (n=125)2.2 ± 6.17
Week 24 (n=531)2.8 ± 4.55
Week 32 (n=191)3.2 ± 5.38
Week 40 (n=218)3.7 ± 4.97
Week 48 (n=210)3.5 ± 5.87
Week 60 (n=148)4.5 ± 6.10
Week 72 (n=116)5.0 ± 6.33
Week 84 (n=64)5.7 ± 6.73
Week 96 (n=41)3.9 ± 6.36
Week 108 (n=19)6.3 ± 6.86
Week 120 (n=7)5.7 ± 9.07
Week 132 (n=4)8.5 ± 8.35
Week 144 (n=1)1.0 ± 0.0
SecondaryChange From Baseline in CD8 Cell Count

Change from baseline in cluster of differentiation 8 suppressor T cells (CD8) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.

Time frame:
Baseline up to Week 144
Reported as:
Mean · cells/uL
Change From Baseline in CD8 Cell Count
cells/uLMaraviroc
Day 2-7 (n=6)268.5 ± 262.50
Week 2 (n=201)78.2 ± 343.85
Week 4 (n=701)205.6 ± 509.70
Week 8 (n=692)345.6 ± 599.98
Week 12 (n=696)309.4 ± 578.91
Week 16 (n=129)259.6 ± 430.78
Week 20 (n=119)325.2 ± 621.46
Week 24 (n=523)251.3 ± 498.85
Week 32 (n=185)185.2 ± 484.74
Week 40 (n=222)160.9 ± 471.99
Week 48 (n=214)153.2 ± 464.73
Week 60 (n=157)76.9 ± 467.64
Week 72 (n=120)68.7 ± 502.73
Week 84 (n=70)-11.6 ± 548.85
Week 96 (n=45)56.6 ± 403.10
Week 108 (n=19)147.5 ± 600.55
Week 120 (n=8)-135.1 ± 517.02
Week 132 (n=4)-363.3 ± 882.30
Week 144 (n=1)642.0 ± 0.0
SecondaryChange From Baseline in CD8 Cell Count Percent

Change from baseline in CD8 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.

Time frame:
Baseline up to Week 144
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD8 Cell Count Percent
percentage of lymphocytesMaraviroc
Day 2-7 (n=6)3.0 ± 3.42
Week 2 (n=197)-1.5 ± 7.68
Week 4 (n=689)-0.3 ± 8.08
Week 8 (n=683)0.4 ± 9.62
Week 12 (n=675)-0.9 ± 9.95
Week 16 (n=125)0.7 ± 8.66
Week 20 (n=115)-0.7 ± 10.08
Week 24 (n=510)-3.2 ± 8.92
Week 32 (n=184)-4.0 ± 9.09
Week 40 (n=215)-4.5 ± 8.90
Week 48 (n=202)-5.1 ± 10.63
Week 60 (n=146)-5.0 ± 11.90
Week 72 (n=113)-6.2 ± 9.87
Week 84 (n=64)-8.2 ± 15.52
Week 96 (n=40)-9.5 ± 10.18
Week 108 (n=19)-14.5 ± 9.99
Week 120 (n=6)-14.5 ± 13.41
Week 132 (n=4)-16.8 ± 12.89
Week 144 (n=1)-2.0 ± 0.0
SecondaryMedian Time to Virologic Failure

Computed as time from the first dose of study medication to the loss of virologic response. Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥ 0.5 log10 copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.

Time frame:
Day 1 up to Week 144
Reported as:
Median · days
Median Time to Virologic Failure
daysMaraviroc
Median Time to Virologic Failure86.5 (58.0 to 169.0)
Statistical analysis
  • Maraviroc · 75th percentile (median): 169.0 · 95% CI 135.0 to 178.0
  • Maraviroc · 50th percentile (median): 86.5 · 95% CI 82.0 to 92.0
  • Maraviroc · 25th percentile (median): 58.0 · 95% CI 57.0 to 62.0
SecondaryPercentage of Participants With Changes in HIV-1 RNA Level in Participants Meeting the Definition of Virologic Failure

Reasons for virologic failure: A) failure to achieve a reduction in HIV-1 RNA\>=0.5 log10 copies/ml from baseline (BL) by second viral load determination (unless below level of quantification \[LOQ\]); B) \>=0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from BL \>0.5 log10 copies/ml ; C) HIV-1 RNA \>1000 copies/ml after having achieved an HIV-1 RNA below LOQ.

Time frame:
Baseline up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Changes in HIV-1 RNA Level in Participants Meeting the Definition of Virologic Failure
percentage of participantsMaraviroc
Reduction in HIV-1 RNA<0.5 log10 copies/ml43.75
>=0.5 log10 increase from nadir in HIV-1 RNA31.77
HIV-1 RNA >1000 copies/ml18.75
Reduction <0.5 log10 + HIV-1 RNA >1000 copies/ml3.13
>=0.5 log10 increase from nadir + HIV-1 RNA >10002.60
SecondaryPercentage of Participants With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure

Tropism status (CCR5 \[R5\], CXCR4 \[X4\], Dual Mixed \[DM\], or Non-reportable \[NR\]) at Screening (Scr) and time of virologic failure (V fail). Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥0.5 log10 copies/mL by second viral load determination (unless viral load was below lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.

Time frame:
Screening up to Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure
percentage of participantsMaraviroc
Scr: Missing; V fail: R55.73
Scr: Missing; V fail: X40.52
Scr: Missing; V fail: DM1.04
Scr: Missing; V fail: NR7.29
Scr: Missing; V fail: Missing1.56
Scr: NR; V fail: R50.52
Scr: R5; V fail: R531.25
Scr: R5; V fail: X44.17
Scr: R5; V fail: DM18.75
Scr: R5; V fail: NR22.92
Scr: R5; V fail: Missing6.25
SecondaryNumber of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau

Resistance to maravroc in viruses from participants failing therapy with R5 virus was investigated using the in vitro phenotypic (drug susceptibility) assay. The number of participants who failed with R5 virus were assessed successfully for maraviroc susceptibility at Baseline and Last on--treatment (Week 144). Samples were analyzed for change from Baseline to time of virologic failure in IC 50 and presence of plateau. A maximal percent inhibition (MPI) \<95% established as a plateau in inhibition at high concentrations of maraviroc was used to identify viruses which had reduced phenotypic susceptibility to maraviroc.

Time frame:
Baseline up to Week 144
Reported as:
Number · participants
Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau
participantsMaraviroc
Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau14
SecondaryNumber of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)

Virus from participants who experienced virologic failure was analyzed for resistance to maraviroc. Resistance testing was performed on archived samples of participants which were available pre--treatment at time of virologic failure. For participants who met definition of virologic failure during the trial, the sequencing of the V3 loop of HIV--1 viral envelope gp 120 was evaluated to identify any amino acid changes concomitant with decreased susceptibility to maraviroc.

Time frame:
Baseline up to Week 144
Reported as:
Number · participants
Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)
participantsMaraviroc
Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)NA

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc—139/1,032 (13.5%)700/1,032 (67.8%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventMaraviroc
PneumoniaInfections and infestations11/1032
PyrexiaGeneral disorders10/1032
DiarrhoeaGastrointestinal disorders7/1032
Chest painGeneral disorders7/1032
AnaemiaBlood and lymphatic system disorders5/1032
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1032
Cytolytic hepatitisHepatobiliary disorders4/1032
Urinary tract infectionInfections and infestations4/1032
Renal failure acuteRenal and urinary disorders4/1032
ThrombocytopeniaBlood and lymphatic system disorders3/1032
Most frequent other events
Showing 10 of 671
Most frequent other events
EventMaraviroc
DiarrhoeaGastrointestinal disorders94/1032
BronchitisInfections and infestations67/1032
HeadacheNervous system disorders66/1032
NauseaGastrointestinal disorders60/1032
PyrexiaGeneral disorders50/1032
CoughRespiratory, thoracic and mediastinal disorders47/1032
Back painMusculoskeletal and connective tissue disorders45/1032
RashSkin and subcutaneous tissue disorders44/1032
NasopharyngitisInfections and infestations41/1032
Upper respiratory tract infectionInfections and infestations41/1032

Baseline characteristics

Age, Continuous
Age, Continuous(years)Maraviroc
Mean45.6 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc
Female205
Male827
Baseline Viral Load: Absolute Value
Baseline Viral Load: Absolute Value(copies/mL)Maraviroc
Overall: Absolute (N=979)117846.1 ± 321426.5
< 100,000: Absolute (N=729)22395.9 ± 25974.4
>= 100,000: Absolute (N=250)396179.0 ± 547142.6
Baseline Viral Load: Absolute Value
Baseline Viral Load: Absolute Value(copies/mL)Maraviroc
Overall: Absolute (N=979)25109.5 (39.0 to 5728492.0)
< 100,000: Absolute (N=729)11028.5 (39.0 to 99643.0)
>= 100,000: Absolute (N=250)234750.0 (100000.0 to 5728492.0)
Baseline Viral Load: Log Scale
Baseline Viral Load: Log Scale(log10 copies/mL)Maraviroc
Overall: Log Scale (N=979)4.259 ± 1.0182
< 100,000: Log Scale (N=729)3.859 ± 0.8517
>= 100,000: Log Scale (N=250)5.423 ± 0.3496
Baseline Viral Load: : Log Scale
Baseline Viral Load: : Log Scale(log10 copies/mL)Maraviroc
Overall: Log Scale (N=979)4.400 (1.591 to 6.758)
< 100,000: Log Scale (N=729)4.043 (1.591 to 4.998)
>= 100,000: Log Scale (N=250)5.371 (5.000 to 6.758)
08

Study locations

361 sites
  • The University of Alabama
    Birmingham, Alabama 35294-2050, United States
  • Health Services Center
    Hobson City, Alabama 36201, United States
  • El Rio, Special Immunology Associates
    Tucson, Arizona 85745, United States
  • Health for Life Clinic PLLC
    Little Rock, Arkansas 72207, United States
  • Thomas T Jefferson, MD
    Little Rock, Arkansas 72207, United States
  • Vista Medical
    Beverly Hills, California 90210-4212, United States
  • AHF Research Center
    Beverly Hills, California 90211, United States
  • Orange County Center for Special Immunology
    Fountain Valley, California 92708, United States
  • Kaiser Permanente
    Hayward, California 94545, United States
  • Living Hope Clinical Trials
    Long Beach, California 90813, United States
  • AltaMed Health Services Corporation
    Los Angeles, California 90022, United States
  • Kaiser Permanente Medical Center
    Los Angeles, California 90027, United States
  • Robert Bolan, MD
    Los Angeles, California 90028, United States
  • Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology
    Los Angeles, California 90033, United States
  • Peter J. Ruane, M.D. Inc.
    Los Angeles, California 90036, United States
  • Synergy Hematology-Oncology Associates
    Los Angeles, California 90036, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc.
    Los Angeles, California 90048, United States
  • Office of Anthony Mills, MD
    Los Angeles, California 90069, United States
  • Office of Dr. Salah Bibi, MD
    Modesto, California 95350, United States
  • Bonnie V Bock MD
    Newport Beach, California 92663, United States
  • Alta Bates Summit Medical Center
    Oakland, California 94609, United States
  • Desert Medical Group, Clinical Research Center
    Palm Springs, California 92262, United States
  • Riverside Medical Clinic
    Riverside, California 92506, United States
  • Fort Sutter Medical Complex
    Sacramento, California 95816, United States
  • Sutter Institute for Medical Research
    Sacramento, California 95816, United States
  • Sutter Medical Group
    Sacramento, California 95816, United States
  • Quest Clinical Research
    San Francisco, California 94115-3029, United States
  • Kaiser Permanente Medical Center
    San Francisco, California 94118, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Shared Medical Research Foundation
    Tarzana, California 91356, United States
  • Tarzana Treatment Center
    Tarzana, California 91356, United States
  • Bipin Bhagat MD Inc.
    Victorville, California 92395, United States
  • Kaiser Permanente Colorado
    Denver, Colorado 80205, United States
  • Kaiser Permanente of Colorado
    Denver, Colorado 80205, United States
  • Denver Infectious Disease Consultants, PLLC
    Denver, Colorado 80220, United States
  • Kaiser Permanente of Colorado
    Lafayette, Colorado 80026, United States
  • Connecticut Health Care Group
    Glastonbury, Connecticut 06033, United States
  • Infectious Disease Clinic
    Norwich, Connecticut 06360, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 20009, United States
  • Internal Medicine Associates of Lee County
    Bonita Springs, Florida 34134, United States
  • Infectious Disease Research Corp
    Boynton Beach, Florida 33426, United States
  • Internal Medicine Associates of Lee County
    Cape Coral, Florida 33990, United States
  • Daniel Warner M.D., P.A. Consultive Medicine
    Daytona Beach, Florida 32117, United States
  • Northpoint Medical, PA
    Fort Lauderdale, Florida 33308, United States
  • Comprehensive Care Center
    Fort Lauderdale, Florida 33311, United States
  • Office of Gary J. Richmond, MD
    Fort Lauderdale, Florida 33316, United States
  • Internal Medicine Associates of Lee County
    Fort Myers, Florida 33912, United States
  • Therafirst Medical Centers
    Ft. Lauderdale, Florida 33308, United States
  • Sunshine Medical Institute
    Hollywood, Florida 33021, United States
  • Osler Medical Inc.
    Melbourne, Florida 32901, United States
  • Office of Albert Canas, MD
    Miami Beach, Florida 33139, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Care Resource
    Miami, Florida 33137, United States
  • Donald Johnson, MD
    North Miami Beach, Florida 33162, United States
  • Wohlfeiler, Piperato & Associates, LLC
    North Miami Beach, Florida 33169, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • Infectious Diseases of Central Florida
    Orlando, Florida 32806, United States
  • Associates in Infectious Diseases
    Port St. Lucie, Florida 34952, United States
  • Barry Rodwick, MD
    Safety Harbor, Florida 34695, United States
  • Infectious Diseases Associates
    Sarasota, Florida 34239, United States
  • University Hepatitis Center at Bach & Godofsky, MD,PA
    Sarasota, Florida 34243, United States
  • All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Eric Nicholson, M.D., P.A.
    Tallahassee, Florida 32308, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • University of Sout Florida
    Tampa, Florida 33612, United States
  • Midtown Medical Center
    Tampa, Florida 33614, United States
  • Donald Watren MD
    West Palm Beach, Florida 33401, United States
  • Philip Brachman MD
    Atlanta, Georgia 30309, United States
  • Family Health Care of Atlanta
    Atlanta, Georgia 30318-2513, United States
  • Midtown West Medical
    Atlanta, Georgia 30318, United States
  • Absolute CARE
    Atlanta, Georgia 30329, United States
  • Kaiser Permanente
    Atlanta, Georgia 30339, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Kaiser Permanente
    Jonesboro, Georgia 30236, United States
  • Infectious Diseases Associates, PC
    Riverdale, Georgia 30274, United States
  • Chatham County Health Department
    Savannah, Georgia 31405, United States
  • Infectious Disease Consultants
    Tucker, Georgia 30084-8128, United States
  • Ruth M. Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Roger Trinh
    Chicago, Illinois 60613, United States
  • Northstar Medical Center
    Chicago, Illinois 60657, United States
  • Cotton-O'Neil Clinic
    Topeka, Kansas 66606-1670, United States
  • Kansas University Internal Medicine Midtown Clinic
    Wichita, Kansas 67214, United States
  • Via Christi Research, Inc.
    Wichita, Kansas 67214, United States
  • Chase Brexton Health Services Inc
    Baltimore, Maryland 21201, United States
  • Metro Health Care
    Greenbelt, Maryland 20770-3525, United States
  • Dr.'s Alpert, Trinh, and Posorske
    Silver Spring, Maryland 20910, United States
  • Tufts - New England Medical Center
    Boston, Massachusetts 02111, United States
  • Fenway Community Health
    Boston, Massachusetts 02115, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02215-3318, United States
  • Community Research Initiative of New England
    Springfield, Massachusetts 01107, United States
  • The Office of Dr. Paul A. Benson, DO
    Berkley, Michigan 48072, United States
  • Private Practice (Dr. Gregory Kuldanek)
    Grand Rapids, Michigan 49546, United States
  • St. John hospital and Medical Center
    Grosse Pointe Woods, Michigan 48236, United States
  • Private Practice
    Keego Harbor, Michigan 48320, United States
  • MSU Adult Medicine, 10
    Lansing, Michigan 48910, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Nemechek Health Renewal
    Kansas City, Missouri 64111, United States
  • Private Practice (Dr. Mark Scheperle)
    St. Louis, Missouri 63117, United States

Showing the first 100 of 361 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2007
First posted
Jan 25, 2007
Start
Feb 2007
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Oct 17, 2011
Last update
Jun 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00426660
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jan 25, 2007
Start date
Feb 2007
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Oct 17, 2011
Last update
Jun 29, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion